EGFR and non-small cell lung carcinoma: More recently, gefitinib, a first‐generation EGFR tyrosine kinase inhibitor (TKI), has been shown its advantage on DFS but not OS of resected ES‐NSCLC patients (most ADC≥90%) with EGFR mutations when compared with pACT.31, 32